BACKGROUND: Noroviruses pose a significant public health risk, particularly in very young individuals, older adults, and individuals with underlying conditions. We assessed 2 bivalent norovirus virus-like particle (VLP) vaccine candidate formulations in healthy adults aged 18-49 years. METHODS:Enrolled subjects (n = 454) randomly assigned among 3 groups received intramuscular placebo (saline) or vaccines containing either 15 µg or 50 µg of GI.1 VLP and 50 µg GII.4 VLP (15/50 and 50/50 formulations) adjuvanted with monophosphoryl lipid A and Al(OH)3 We present safety and immunogenicity assessments up to 28 days after vaccination. RESULTS: No vaccine-related serious adverse events or adverse events of special interest were reported. Reactions were mainly mild to moderate, the most frequent being transient pain, in 8%, 64%, and 73% of placebo, 15/50, and 50/50 groups, respectively; transient myalgia, headache, and fatigue were the commonest systemic adverse events. Subjects assessed per protocol (n = 442) displayed rapid immune responses to vaccination, peaking by days 7-10 and persisting through day 28. GI.1 responses were highest with the 50/50 formulation, but GII.4 responses were higher with the 15/50 formulation. CONCLUSIONS: Both candidate VLP vaccines were well tolerated and elicited robust immune responses by 7-10 days that persisted through day 28. The 15/50 formulation displayed the best balance of tolerability and immunogenicity. CLINICAL TRIALS REGISTRATION: NCT02142504.
RCT Entities:
BACKGROUND: Noroviruses pose a significant public health risk, particularly in very young individuals, older adults, and individuals with underlying conditions. We assessed 2 bivalent norovirus virus-like particle (VLP) vaccine candidate formulations in healthy adults aged 18-49 years. METHODS: Enrolled subjects (n = 454) randomly assigned among 3 groups received intramuscular placebo (saline) or vaccines containing either 15 µg or 50 µg of GI.1 VLP and 50 µg GII.4 VLP (15/50 and 50/50 formulations) adjuvanted with monophosphoryl lipid A and Al(OH)3 We present safety and immunogenicity assessments up to 28 days after vaccination. RESULTS: No vaccine-related serious adverse events or adverse events of special interest were reported. Reactions were mainly mild to moderate, the most frequent being transient pain, in 8%, 64%, and 73% of placebo, 15/50, and 50/50 groups, respectively; transient myalgia, headache, and fatigue were the commonest systemic adverse events. Subjects assessed per protocol (n = 442) displayed rapid immune responses to vaccination, peaking by days 7-10 and persisting through day 28. GI.1 responses were highest with the 50/50 formulation, but GII.4 responses were higher with the 15/50 formulation. CONCLUSIONS: Both candidate VLP vaccines were well tolerated and elicited robust immune responses by 7-10 days that persisted through day 28. The 15/50 formulation displayed the best balance of tolerability and immunogenicity. CLINICAL TRIALS REGISTRATION: NCT02142504.
Authors: John J Treanor; Robert L Atmar; Sharon E Frey; Robert Gormley; Wilbur H Chen; Jennifer Ferreira; Robert Goodwin; Astrid Borkowski; Ralf Clemens; Paul M Mendelman Journal: J Infect Dis Date: 2014-06-20 Impact factor: 5.226
Authors: Amanda Reeck; Owen Kavanagh; Mary K Estes; Antone R Opekun; Mark A Gilger; David Y Graham; Robert L Atmar Journal: J Infect Dis Date: 2010-10-15 Impact factor: 5.226
Authors: Gabriel I Parra; Karin Bok; Ross Taylor; Joel R Haynes; Stanislav V Sosnovtsev; Charles Richardson; Kim Y Green Journal: Vaccine Date: 2012-03-31 Impact factor: 3.641
Authors: Vishnu C Damalanka; Yunjeong Kim; Anushka C Galasiti Kankanamalage; Gerald H Lushington; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Kyeong-Ok Chang; William C Groutas Journal: Eur J Med Chem Date: 2016-12-21 Impact factor: 6.514
Authors: Anushka C Galasiti Kankanamalage; Yunjeong Kim; Athri D Rathnayake; Vishnu C Damalanka; Pathum M Weerawarna; Sean T Doyle; Amer F Alsoudi; D M Padmasankha Dissanayake; Gerald H Lushington; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Kyeong-Ok Chang; William C Groutas Journal: Eur J Med Chem Date: 2016-11-14 Impact factor: 6.514
Authors: Daniel Olson; Molly M Lamb; Maria Renee Lopez; M Alejandra Paniagua-Avila; Alma Zacarias; Gabriela Samayoa-Reyes; Celia Cordon-Rosales; Edwin J Asturias Journal: Open Forum Infect Dis Date: 2017-03-17 Impact factor: 3.835
Authors: Sasirekha Ramani; Frederick H Neill; Jennifer Ferreira; John J Treanor; Sharon E Frey; David J Topham; Robert R Goodwin; Astrid Borkowski; Frank Baehner; Paul M Mendelman; Mary K Estes; Robert L Atmar Journal: Clin Vaccine Immunol Date: 2017-05-05
Authors: Geert Leroux-Roels; Jakob P Cramer; Paul M Mendelman; James Sherwood; Ralf Clemens; Annelies Aerssens; Ilse De Coster; Astrid Borkowski; Frank Baehner; Pierre Van Damme Journal: J Infect Dis Date: 2018-01-30 Impact factor: 5.226